Flaxseed Lignan-Enriched Complex Products in Chronic Disease

Archer Daniels Midland has expressed a willingness to work with any company interested in resuming production of BeneFlax®. We are seeking the interest of investors to revive the technology and resume production of BeneFlax® or a BeneFlax® like product. We believe that the market is now more receptive to this product than it was 8 years ago and the new science including the current studies at the University of Saskatchewan supports an expanded range of uses for BeneFlax® including as a sole therapeutic, an adjuvant therapy, or chemopreventative for chronic disease such as risk factors for cardiovascular disease (e.g. hypercholesterolemia, hypertension) and inflammatory conditions of the gastrointestinal tract, such as inflammatory bowel disease.